Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Blood Specimen Collection × Lymphoid × Clear all

Phase

Phase NA 22 Phase 1 2 Phase EARLY_PHASE1 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5 Breast 4 Thoracic 3 Tumor-Agnostic 2 Sarcoma 2 Plasma cell 2 Other hematologic neoplasm 2 Gynecologic 2 Genitourinary 2 Dermatologic 2 CNS 2 Myeloid 1 Lymphoid 1 Endocrine 1

Conditions

Multiple Myeloma 1 Lymphoma 1

Interventions

Rituximab 587 Cyclophosphamide 513 Etoposide 234 Vincristine 230 Doxorubicin 224 Cytarabine 194 Prednisone 183 Methotrexate 175 Filgrastim 160 fludarabine 151 Dexamethasone 151 fludarabine phosphate 149 Lenalidomide 141 Radiotherapy 113 Melphalan 106 Peripheral Blood Stem Cell Transplantation 101 Bendamustine Hydrochloride 101 Busulfan 100 Bortezomib 94 ibrutinib 93 Mycophenolic Acid 91 Granulocyte Colony-Stimulating Factor 91 venetoclax 89 obinutuzumab 86 Whole-Body Irradiation 86 Tacrolimus 77 Gemcitabine 76 zanubrutinib 69 Carmustine 63 Brentuximab Vedotin 63

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02260414 2017-05-11

METRO B

Centre Hospitalier Universitaire de Saint Etienne

Phase 2 Completed

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡